Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ESPR Stock Forecast 2025-2026
$3.73
Current Price
$884.27M
Market Cap
Buy 6
Hold 1
Sell 1
Wall St Analyst Ratings
Distance to ESPR Price Targets
+329.0%
To High Target of $16.00
+24.7%
To Median Target of $4.65
-53.9%
To Low Target of $1.72
ESPR Price Momentum
-7.0%
1 Week Change
+40.2%
1 Month Change
+7.2%
1 Year Change
+69.5%
Year-to-Date Change
-7.4%
From 52W High of $4.03
+440.6%
From 52W Low of $0.69
📊 TOP ANALYST CALLS
Did ESPR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Esperion is one of their latest high-conviction picks.
Latest ESPR Stock Price Targets & Analyst Predictions
Based on our analysis of 21 Wall Street analysts, ESPR has a bullish consensus with a median price target of $4.65 (ranging from $1.72 to $16.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $3.73, the median forecast implies a 24.7% upside. This outlook is supported by 6 Buy, 1 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 329.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ESPR Analyst Ratings
6
Buy
1
Hold
1
Sell
ESPR Price Target Range
Low
$1.72
Average
$4.65
High
$16.00
Current: $3.73
Latest ESPR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ESPR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 25, 2025 | Piper Sandler | David Amsellem | Overweight | Initiates | $9.00 |
| Sep 19, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Jun 17, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| May 7, 2025 | Needham | Serge Belanger | Buy | Maintains | $4.00 |
| Apr 25, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Apr 25, 2025 | Needham | Serge Belanger | Buy | Reiterates | $5.00 |
| Apr 17, 2025 | Goldman Sachs | Paul Choi | Neutral | Maintains | $3.00 |
| Apr 8, 2025 | Needham | Serge Belanger | Buy | Reiterates | $5.00 |
| Mar 20, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Mar 5, 2025 | Citizens Capital Markets | Jason Butler | Market Outperform | Reiterates | $4.00 |
| Mar 4, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Feb 11, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $4.00 |
| Feb 11, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Jan 23, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Jan 23, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $7.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 10, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $N/A |
| Dec 18, 2024 | Goldman Sachs | Paul Choi | Neutral | Reinstates | $4.00 |
| Dec 17, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Initiates | $8.00 |
| Dec 13, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
Esperion Therapeutics Inc. (ESPR) Competitors
The following stocks are similar to Esperion based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Esperion Therapeutics Inc. (ESPR) Financial Data
Esperion Therapeutics Inc. has a market capitalization of $884.27M with a P/E ratio of -13.3x. The company generates $303.80M in trailing twelve-month revenue with a -34.8% profit margin.
Revenue growth is +69.1% quarter-over-quarter, while maintaining an operating margin of -11.4% and return on equity of +13.3%.
Valuation Metrics
Market Cap
$884.27M
Enterprise Value
$1.39B
P/E Ratio
-13.3x
PEG Ratio
-2.0x
Price/Sales
2.9x
Growth & Margins
Revenue Growth (YoY)
+69.1%
Gross Margin
+52.7%
Operating Margin
-11.4%
Net Margin
-34.8%
EPS Growth
+69.1%
Financial Health
Cash/Price Ratio
+10.5%
Current Ratio
1.0x
Debt/Equity
-1.3x
ROE
+13.3%
ROA
-5.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Esperion Therapeutics Inc. (ESPR) Business Model
About Esperion Therapeutics Inc.
What They Do
Develops innovative lipid-lowering therapies.
Business Model
Esperion Therapeutics generates revenue by developing and commercializing oral medications aimed at managing cholesterol levels, specifically targeting patients who cannot achieve their cholesterol goals with existing treatments. The company focuses on a non-statin therapy that presents a unique mechanism of action, catering to statin-intolerant individuals and those needing additional support for cardiovascular health.
Additional Information
Based in Ann Arbor, Michigan, Esperion is dedicated to improving patient compliance and outcomes through convenient dosing and actively engages with healthcare professionals to align its products with the latest medical research and treatment protocols. The company's innovative approach positions it as a significant player in the cardiovascular pharmaceutical market.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
304
CEO
Mr. Sheldon L. Koenig M.B.A.
Country
United States
IPO Year
2013
Website
www.esperion.comEsperion Therapeutics Inc. (ESPR) Latest News & Analysis
Latest News
Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript
17 days ago
Quick Summary
Esperion Therapeutics, Inc. (ESPR) will participate in the Jefferies London Healthcare Conference on November 18, 2025, with CFO Benjamin Halladay presenting.
Why It Matters
Esperion Therapeutics' participation in the Jefferies London Healthcare Conference highlights its visibility in the healthcare sector, potentially influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Esperion's partner HLS Therapeutics has received Health Canada approval to market NILEMDO for LDL-Cholesterol reduction, with a commercial launch expected in Q2 2026.
Why It Matters
Approval of NILEMDO in Canada boosts Esperion's market potential and revenue prospects, signaling growth opportunities in the cardiovascular treatment sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Esperion Therapeutics discussed efforts to address statin intolerance and improve cardiovascular health during a conference call on November 11, 2025.
Why It Matters
Esperion's focus on statin intolerance and cardiovascular health could enhance its market position, attracting investor interest in potential growth and innovation in the pharmaceutical sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Esperion Therapeutics, C4 Therapeutics, and SiTime Corp. contributed positively to performance, while Monday.com Ltd. was the largest detractor for the quarter.
Why It Matters
Top performers like Esperion and SiTime boost confidence in growth sectors, while underperformers like Monday.com may signal volatility risks. This impacts overall fund sentiment and investment strategies.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Esperion Therapeutics (ESPR) is still considered a buy, supported by strong cardiovascular drug franchises. Upcoming Q4 results are critical for profitability, with attractive valuation and growth prospects.
Why It Matters
Esperion Therapeutics shows potential for growth with strong drug franchises and an attractive valuation, despite recent challenges. Q4 results will be crucial for confirming profitability and market confidence.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Esperion Therapeutics, Inc. (ESPR) will hold its Q3 2025 earnings call on November 6, 2025, at 8:00 AM EST, featuring key executives and analysts from various financial institutions.
Why It Matters
Earnings calls provide insights into a company's financial health and future prospects. Investor questions can reveal market sentiment and analyst expectations for Esperion's performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About ESPR Stock
What is Esperion Therapeutics Inc.'s (ESPR) stock forecast for 2026?
Based on our analysis of 21 Wall Street analysts, Esperion Therapeutics Inc. (ESPR) has a median price target of $4.65. The highest price target is $16.00 and the lowest is $1.72.
Is ESPR stock a good investment in 2026?
According to current analyst ratings, ESPR has 6 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $3.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ESPR stock?
Wall Street analysts predict ESPR stock could reach $4.65 in the next 12 months. This represents a 24.7% increase from the current price of $3.73. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Esperion Therapeutics Inc.'s business model?
Esperion Therapeutics generates revenue by developing and commercializing oral medications aimed at managing cholesterol levels, specifically targeting patients who cannot achieve their cholesterol goals with existing treatments. The company focuses on a non-statin therapy that presents a unique mechanism of action, catering to statin-intolerant individuals and those needing additional support for cardiovascular health.
What is the highest forecasted price for ESPR Esperion Therapeutics Inc.?
The highest price target for ESPR is $16.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 329.0% increase from the current price of $3.73.
What is the lowest forecasted price for ESPR Esperion Therapeutics Inc.?
The lowest price target for ESPR is $1.72 from at , which represents a -53.9% decrease from the current price of $3.73.
What is the overall ESPR consensus from analysts for Esperion Therapeutics Inc.?
The overall analyst consensus for ESPR is bullish. Out of 21 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $4.65.
How accurate are ESPR stock price projections?
Stock price projections, including those for Esperion Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 3:55 PM UTC